Nautilus Biotechnology Stock Probability of Future Stock Price Finishing Over 6.77
| NAUT Stock | USD 2.40 0.02 0.84% |
Nautilus |
Nautilus Biotechnology Target Price Odds to finish over 6.77
The tendency of Nautilus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 6.77 or more in 90 days |
| 2.40 | 90 days | 6.77 | close to zero percent |
Based on a normal probability distribution, the odds of Nautilus Biotechnology to move over $ 6.77 or more in 90 days from now is close to zero percent (This Nautilus Biotechnology probability density function shows the probability of Nautilus Stock to fall within a particular range of prices over 90 days) . Probability of Nautilus Biotechnology price to stay between its current price of $ 2.40 and $ 6.77 at the end of the 90-day period is more than 94.0 .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.7 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Nautilus Biotechnology will likely underperform. Additionally Nautilus Biotechnology has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Nautilus Biotechnology Price Density |
| Price |
Predictive Modules for Nautilus Biotechnology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Nautilus Biotechnology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Nautilus Biotechnology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Nautilus Biotechnology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Nautilus Biotechnology is not an exception. The market had few large corrections towards the Nautilus Biotechnology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Nautilus Biotechnology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Nautilus Biotechnology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.26 | |
β | Beta against Dow Jones | 2.70 | |
σ | Overall volatility | 0.19 | |
Ir | Information ratio | -0.01 |
Nautilus Biotechnology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Nautilus Biotechnology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Nautilus Biotechnology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Nautilus Biotechnology generated a negative expected return over the last 90 days | |
| Nautilus Biotechnology has high historical volatility and very poor performance | |
| Net Loss for the year was (63.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nautilus Biotechnology currently holds about 299.34 M in cash with (51.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.4. | |
| Nautilus Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Roughly 33.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Sujal Patel of 9267 shares of Nautilus Biotechnology at 2.7014 subject to Rule 16b-3 |
Nautilus Biotechnology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Nautilus Stock often depends not only on the future outlook of the current and potential Nautilus Biotechnology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Nautilus Biotechnology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 124.9 M | |
| Cash And Short Term Investments | 173.4 M |
Nautilus Biotechnology Technical Analysis
Nautilus Biotechnology's future price can be derived by breaking down and analyzing its technical indicators over time. Nautilus Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Nautilus Biotechnology. In general, you should focus on analyzing Nautilus Stock price patterns and their correlations with different microeconomic environments and drivers.
Nautilus Biotechnology Predictive Forecast Models
Nautilus Biotechnology's time-series forecasting models is one of many Nautilus Biotechnology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Nautilus Biotechnology's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Nautilus Biotechnology
Checking the ongoing alerts about Nautilus Biotechnology for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Nautilus Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Nautilus Biotechnology generated a negative expected return over the last 90 days | |
| Nautilus Biotechnology has high historical volatility and very poor performance | |
| Net Loss for the year was (63.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nautilus Biotechnology currently holds about 299.34 M in cash with (51.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.4. | |
| Nautilus Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Roughly 33.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Sujal Patel of 9267 shares of Nautilus Biotechnology at 2.7014 subject to Rule 16b-3 |
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.